BibTex format
@article{Lam:2026:10.1002/anie.6507556,
author = {Lam, P-L and Yeung, Y-H and Kai, H-Y and Xie, Y and Liu, Z and Elliott, SJ and Walter, ERH and Liu, F and Zhou, W and Wu, Y and Jiao, J and Chau, H-F and Law, G-L and Long, NJ and Bünzli, J-CG and Wong, K-L},
doi = {10.1002/anie.6507556},
journal = {Angew Chem Int Ed Engl},
title = {Facile Synthesis of a Bis-α-aryl-Substituted Pyclen-Based Heptadentate Lanthanide Chelator for Ultra-Robust and High-Contrast MRI Agents and for Radiopharmaceuticals.},
url = {http://dx.doi.org/10.1002/anie.6507556},
year = {2026}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - Owing to safety concerns associated with previous gadolinium-based magnetic resonance imaging (MRI) agents, pyclen-based Gd chelates are emerging as promising alternatives. However, the development of pyclen-based chelators has been hindered by synthetic challenges. In this work, we report two new pyclen-based chelators featuring α-aryl-substituents on two of the acetate arms. Using the Petasis reaction, two lanthanide chelators 3a and 3b were synthesized in just two steps from pyclen. 3a-Gd exhibits superior coordination stability and relaxivity compared to previously reported Gd3+ chelates of comparable molecular weight. It also has low cytotoxicity and produces a strong, long-lasting in vivo MRI signal, enabling real-time monitoring of tissues/organs, as demonstrated in heart, liver, and kidney imaging of mice. Additionally, the chelator also shows improved coordination kinetics for In3+, Tb3+, Lu3+, and Y3+, highlighting its potential for the development of a new class of next-generation radiopharmaceuticals.
AU - Lam,P-L
AU - Yeung,Y-H
AU - Kai,H-Y
AU - Xie,Y
AU - Liu,Z
AU - Elliott,SJ
AU - Walter,ERH
AU - Liu,F
AU - Zhou,W
AU - Wu,Y
AU - Jiao,J
AU - Chau,H-F
AU - Law,G-L
AU - Long,NJ
AU - Bünzli,J-CG
AU - Wong,K-L
DO - 10.1002/anie.6507556
PY - 2026///
TI - Facile Synthesis of a Bis-α-aryl-Substituted Pyclen-Based Heptadentate Lanthanide Chelator for Ultra-Robust and High-Contrast MRI Agents and for Radiopharmaceuticals.
T2 - Angew Chem Int Ed Engl
UR - http://dx.doi.org/10.1002/anie.6507556
UR - https://www.ncbi.nlm.nih.gov/pubmed/42958817
ER -
